1. Unraveling innovation potential in the real-world setting: eighteen novel agents with twenty-six approved European indications, in the management of leukemias, lymphomas, and multiple myeloma
   Ioannis Petrakis et al, 2019, Expert Review of Hematology CrossRef
2. Epigenetics of Cisplatin Resistance
   Steven G. Gray, 2015, Epigenetic Cancer Therapy CrossRef
3. Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis
   Pin-Fang He et al, 2017, Oncotarget CrossRef
4. Very-Low-Dose Decitabine Is Effective in Treating Intermediate- or High-Risk Myelodysplastic Syndrome
   Hongmin Li et al, 2017, Acta Haematologica CrossRef
5. Low-dose decitabine for previously untreated acute myeloid leukemia ineligible for intensive chemotherapy aged 65 years or older: a prospective study based on comprehensive geriatric assessment
   Ru Feng et al, 2023, Therapeutic Advances in Hematology CrossRef
6. Very-low-dose decitabine treatment for patients with intermediate- or high-risk myelodysplastic syndrome: a retrospective analysis of thirteen cases
   Kaiji Zhang et al, 2020, Annals of Hematology CrossRef